This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Arena Pharmaceuticals, Inc.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Glen Marquez: Innovator in Pharmaceutical Development
Introduction
Glen Marquez is a notable inventor based in San Jose, CA, who has made significant contributions to the field of pharmaceuticals. His work primarily focuses on the development of innovative treatments for various disorders, particularly those related to the GPR119 receptor.
Latest Patents
Glen Marquez holds a patent for "Modulators of the GPR119 receptor and the treatment of disorders related thereto." This invention includes GPR119 receptor agonists such as 3-fluoro-4-(5-fluoro-6-(4-3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide, among others. These compounds are designed to be used as single pharmaceutical agents or in combination with other agents to treat conditions like type 2 diabetes, obesity, and various metabolic-related disorders.
Career Highlights
Glen Marquez is currently employed at Arena Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His innovative approach to pharmaceutical science has positioned him as a key player in the industry.
Collaborations
Throughout his career, Glen has collaborated with esteemed colleagues such as Robert M. Jones and Juerg Lehmann. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.
Conclusion
Glen Marquez's contributions to pharmaceutical innovation, particularly through his patent on GPR119 receptor modulators, highlight his commitment to improving treatment options for various health conditions. His work at Arena Pharmaceuticals, Inc. continues to pave the way for advancements in medical science.